Jane Street Group LLC Lowers Stock Holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Jane Street Group LLC lessened its stake in Organogenesis Holdings Inc. (NASDAQ:ORGO) by 50.4% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 46,866 shares of the company’s stock after selling 47,671 shares during the quarter. Jane Street Group LLC’s holdings in Organogenesis were worth $134,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Captrust Financial Advisors purchased a new position in shares of Organogenesis in the 3rd quarter valued at about $36,000. Delap Wealth Advisory LLC purchased a new position in shares of Organogenesis in the 2nd quarter valued at about $40,000. Intech Investment Management LLC purchased a new position in shares of Organogenesis in the 3rd quarter valued at about $43,000. Pallas Capital Advisors LLC boosted its stake in shares of Organogenesis by 70.8% in the 3rd quarter. Pallas Capital Advisors LLC now owns 21,823 shares of the company’s stock valued at $63,000 after buying an additional 9,048 shares during the period. Finally, Mackenzie Financial Corp boosted its stake in shares of Organogenesis by 46.1% in the 2nd quarter. Mackenzie Financial Corp now owns 24,328 shares of the company’s stock valued at $68,000 after buying an additional 7,678 shares during the period. Hedge funds and other institutional investors own 49.57% of the company’s stock.

Organogenesis Stock Performance

Shares of ORGO opened at $3.00 on Tuesday. The stock has a 50-day simple moving average of $3.50 and a 200-day simple moving average of $3.08. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. The stock has a market capitalization of $377.18 million, a PE ratio of -50.00 and a beta of 1.77. Organogenesis Holdings Inc. has a 1 year low of $2.16 and a 1 year high of $4.57.

Organogenesis (NASDAQ:ORGO) last issued its earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.11. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. The business had revenue of $115.18 million for the quarter, compared to analyst estimates of $109.59 million. During the same quarter last year, the company earned $0.02 EPS. On average, analysts predict that Organogenesis Holdings Inc. will post -0.07 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Gary S. Gillheeney sold 55,615 shares of Organogenesis stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $3.36, for a total value of $186,866.40. Following the sale, the chief executive officer now directly owns 3,044,779 shares in the company, valued at $10,230,457.44. The trade was a 1.79 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 278,116 shares of company stock valued at $991,190 over the last quarter. Company insiders own 36.90% of the company’s stock.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.